BOXR1030, an anti-GPC3 CAR with exogenous GOT2 expression, shows enhanced T cell metabolism and improved anti-cell line derived tumor xenograft activity
Taylor L Hickman, Eugene Choi, Kathleen R Whiteman, Sujatha Muralidharan, Tapasya Pai, Tyler Johnson, Avani Parikh, Taylor Friedman, Madaline Gilbert, Binzhang Shen, Luke Barron, Kathleen E McGinness, Seth A Ettenberg, Greg T Motz, Glen J Weiss, Amy Jensen-Smith, Taylor L Hickman, Eugene Choi, Kathleen R Whiteman, Sujatha Muralidharan, Tapasya Pai, Tyler Johnson, Avani Parikh, Taylor Friedman, Madaline Gilbert, Binzhang Shen, Luke Barron, Kathleen E McGinness, Seth A Ettenberg, Greg T Motz, Glen J Weiss, Amy Jensen-Smith
Abstract
Purpose: The solid tumor microenvironment (TME) drives T cell dysfunction and inhibits the effectiveness of immunotherapies such as chimeric antigen receptor-based T cell (CAR T) cells. Early data has shown that modulation of T cell metabolism can improve intratumoral T cell function in preclinical models.
Experimental design: We evaluated GPC3 expression in human normal and tumor tissue specimens. We developed and evaluated BOXR1030, a novel CAR T therapeutic co-expressing glypican-3 (GPC3)-targeted CAR and exogenous glutamic-oxaloacetic transaminase 2 (GOT2) in terms of CAR T cell function both in vitro and in vivo.
Results: Cell surface expression of tumor antigen GPC3 was observed by immunohistochemical staining in tumor biopsies from hepatocellular carcinoma, liposarcoma, squamous lung cancer, and Merkel cell carcinoma patients. Compared to control GPC3 CAR alone, BOXR1030 (GPC3-targeted CAR T cell that co-expressed GOT2) demonstrated superior in vivo efficacy in aggressive solid tumor xenograft models, and showed favorable attributes in vitro including an enhanced cytokine production profile, a less-differentiated T cell phenotype with lower expression of stress and exhaustion markers, an enhanced metabolic profile and increased proliferation in TME-like conditions.
Conclusions: Together, these results demonstrated that co-expression of GOT2 can substantially improve the overall antitumor activity of CAR T cells by inducing broad changes in cellular function and phenotype. These data show that BOXR1030 is an attractive approach to targeting select solid tumors. To this end, BOXR1030 will be explored in the clinic to assess safety, dose-finding, and preliminary efficacy (NCT05120271).
Conflict of interest statement
I have read the journal’s policy and the authors of this manuscript have the following competing interests: TLH is an employee of Takeda Pharmaceuticals, a former employee of Unum Therapeutics, has ownership interest in Unum Therapeutics (now Cogent Biosciences), and has issued patents: PCT/US18/00028 and PCT/US2018/015999-all outside the submitted work. EC is an employee of Catamaran Bio, Inc, a former employee of Unum Therapeutics; has ownership interest in Unum Therapeutics (now Cogent Biosciences) and Catamaran Bio, Inc; and has issued patents: PCT/US2010/0041032A1, PCT/US2019/0153061A1, PCT/US2019/0105348A1, and PCT/US2019/0284298A1-all outside the submitted work. KRW is an employee of SOTIO Biotech Inc., a former employee of Unum Therapeutics; has ownership interest in Unum Therapeutics (now Cogent Biosciences) and has issued patents: PCT/US2012/0282175A1 and PCT/US2010/0028346A1 all outside the submitted work. SM is an employee of SOTIO Biotech Inc., a former employee of Kiniksa Pharmaceuticals. TP is an employee of Novartis and a former employee of Unum therapeutics. TJ is an employee of Novartis, a former employee of Unum Therapeutics, and has ownership interest in Unum Therapeutics (now Cogent Biosciences). TF is an employee of Biogen and a former employee of Unum therapeutics. MG is an employee of Arrakis Therapeutics and a former employee of Unum therapeutics. BS is an employee of Tango Therapeutics, a former employee of Unum Therapeutics, and has issued patents: US9464333, US9388422, US9303250, WO2014055778A2, WO2016069774A1, and WO2017049094A1-all outside the submitted work. LB is an employee of Catamaran Bio, Inc. and a former employee of Unum therapeutics. KEM is an employee of Arrakis Therapeutics, a former employee of Unum Therapeutics, and a consultant for SOTIO Biotech Inc.; has ownership interest in Unum Therapeutics (now Cogent Biosciences), and ownership interests in Baxter International and Takeda Pharmaceutical Co. outside the submitted work; is an inventor multiple patents PCT/US2019/046550, PCT/US2019/050013, PCT/US2019/040346, and PCT/US2019/060287 related to the submitted work; and US 8,252,913, US 8,461,318, US 8,598,327, US 10,144,770, PCT/US2019/044512, PCT/US2018/015999, PCT/US2017/023064, PCT/US2010/023599-outside of the submitted work. SAE is an employee of BlueRock Therapeutics, a former employee of Unum Therapeutics, has ownership interest in Unum Therapeutics (now Cogent Biosciences), and is a co-inventor on patents filed related to this work. GTM is an employee of BlueRock Therapeutics, a former employee of Unum Therapeutics; has ownership interest in Unum Therapeutics (now Cogent Biosciences), and is a named inventor on many CAR-T patents. GJW is an employee of SOTIO Biotech Inc., a former employee of Unum Therapeutics; reports personal fees from Spring Bank Pharmaceuticals, Imaging Endpoints II, MiRanostics Consulting, Gossamer Bio, Paradigm, International Genomics Consortium, Angiex, IBEX Medical Analytics, GLG Council, Guidepoint Global, Genomic Health, Rafael Pharmaceuticals, SPARC-all outside this submitted work; has ownership interest in Unum Therapeutics (now Cogent Biosciences), and ownership interests in MiRanostics Consulting, Exact Sciences, Moderna, Agenus, Aurinia Pharmaceuticals, and Circulogene-outside the submitted work; and has issued patents: PCT/US2008/072787, PCT/US2010/043777, PCT/US2011/020612, and PCT/US2011/037616-all outside the submitted work and is an inventor on a patent filed related to this work. AJS is an employee of SOTIO Biotech Inc.; a former employee of bluebird bio; has ownership interest in bluebird bio, Pfizer, Regeneron, Exelixis, Bristol Myers Squibb, Celgene, and Alkermes-all outside the submitted work. All other authors have no other competing interests related to this work. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Figures
References
- June CH, Sadelain M. Chimeric Antigen Receptor Therapy. N Engl J Med. N Engl J Med; 2018;379: 64–73. doi: 10.1056/NEJMra1706169
- Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, et al.. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res. Clin Cancer Res; 2006;12: 6106–15. doi: 10.1158/1078-0432.CCR-06-1183
- Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. Elsevier; 2010;18: 843–51. doi: 10.1038/mt.2010.24
- O’Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, et al.. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. Sci Transl Med; 2017;9. doi: 10.1126/scitranslmed.aaa0984
- D’Aloia MM, Zizzari IG, Sacchetti B, Pierelli L, Alimandi M. CAR-T cells: the long and winding road to solid tumors. Cell Death Dis. Cell Death Dis; 2018;9: 282. doi: 10.1038/s41419-018-0278-6
- Le Bourgeois T, Strauss L, Aksoylar H-I, Daneshmandi S, Seth P, Patsoukis N, et al.. Targeting T Cell Metabolism for Improvement of Cancer Immunotherapy. Front Oncol. Front Oncol; 2018;8: 237. doi: 10.3389/fonc.2018.00237
- Knochelmann HM, Smith AS, Dwyer CJ, Wyatt MM, Mehrotra S, Paulos CM. CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies. Front Immunol. Front Immunol; 2018;9: 1740. doi: 10.3389/fimmu.2018.01740
- Martinez M, Moon EK. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment. Front Immunol. Front Immunol; 2019;10: 128. doi: 10.3389/fimmu.2019.00128
- Henze J, Tacke F, Hardt O, Alves F, Al Rawashdeh W. Enhancing the Efficacy of CAR T Cells in the Tumor Microenvironment of Pancreatic Cancer. Cancers (Basel). Multidisciplinary Digital Publishing Institute (MDPI); 2020;12. doi: 10.3390/cancers12061389
- Motz GT, Coukos G. Deciphering and reversing tumor immune suppression. Immunity. Immunity; 2013;39: 61–73. doi: 10.1016/j.immuni.2013.07.005
- Thommen DS, Schumacher TN. T Cell Dysfunction in Cancer. Cancer Cell. Cancer Cell; 2018;33: 547–562. doi: 10.1016/j.ccell.2018.03.012
- Jenkins Y, Zabkiewicz J, Ottmann O, Jones N. Tinkering under the Hood: Metabolic Optimisation of CAR-T Cell Therapy. Antibodies (Basel, Switzerland). Antibodies (Basel); 2021;10. doi: 10.3390/antib10020017
- Rostamian H, Fallah-Mehrjardi K, Khakpoor-Koosheh M, Pawelek JM, Hadjati J, Brown CE, et al.. A metabolic switch to memory CAR T cells: Implications for cancer treatment. Cancer Lett. Cancer Lett; 2021;500: 107–118. doi: 10.1016/j.canlet.2020.12.004
- Pellegrino M, Del Bufalo F, De Angelis B, Quintarelli C, Caruana I, de Billy E. Manipulating the Metabolism to Improve the Efficacy of CAR T-Cell Immunotherapy. Cells. Cells; 2020;10. doi: 10.3390/cells10010014
- Bengsch B, Johnson AL, Kurachi M, Odorizzi PM, Pauken KE, Attanasio J, et al.. Bioenergetic Insufficiencies Due to Metabolic Alterations Regulated by the Inhibitory Receptor PD-1 Are an Early Driver of CD8(+) T Cell Exhaustion. Immunity. Immunity; 2016;45: 358–73. doi: 10.1016/j.immuni.2016.07.008
- Fultang L, Booth S, Yogev O, Martins da Costa B, Tubb V, Panetti S, et al.. Metabolic engineering against the arginine microenvironment enhances CAR-T cell proliferation and therapeutic activity. Blood. Content Repository Only!; 2020;136: 1155–1160. doi: 10.1182/blood.2019004500
- Rostamian H, Khakpoor-Koosheh M, Fallah-Mehrjardi K, Mirzaei HR, Brown CE. Mitochondria as Playmakers of CAR T-cell Fate and Longevity. Cancer Immunol Res. Cancer Immunol Res; 2021;9: 856–861. doi: 10.1158/2326-6066.CIR-21-0110
- Chang C-H, Qiu J, O’Sullivan D, Buck MD, Noguchi T, Curtis JD, et al.. Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell. Cell; 2015;162: 1229–41. doi: 10.1016/j.cell.2015.08.016
- Ma EH, Bantug G, Griss T, Condotta S, Johnson RM, Samborska B, et al.. Serine Is an Essential Metabolite for Effector T Cell Expansion. Cell Metab. Cell Metab; 2017;25: 345–357. doi: 10.1016/j.cmet.2016.12.011
- Johnson MO, Wolf MM, Madden MZ, Andrejeva G, Sugiura A, Contreras DC, et al.. Distinct Regulation of Th17 and Th1 Cell Differentiation by Glutaminase-Dependent Metabolism. Cell. Cell; 2018;175: 1780–1795.e19. doi: 10.1016/j.cell.2018.10.001
- Klysz D, Tai X, Robert PA, Craveiro M, Cretenet G, Oburoglu L, et al.. Glutamine-dependent α-ketoglutarate production regulates the balance between T helper 1 cell and regulatory T cell generation. Sci Signal. Sci Signal; 2015;8: ra97. doi: 10.1126/scisignal.aab2610
- Geiger R, Rieckmann JC, Wolf T, Basso C, Feng Y, Fuhrer T, et al.. L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity. Cell. Cell; 2016;167: 829–842.e13. doi: 10.1016/j.cell.2016.09.031
- Son J, Lyssiotis CA, Ying H, Wang X, Hua S, Ligorio M, et al.. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature. Nature; 2013;496: 101–5. doi: 10.1038/nature12040
- van Karnebeek CDM, Ramos RJ, Wen X-Y, Tarailo-Graovac M, Gleeson JG, Skrypnyk C, et al.. Bi-allelic GOT2 Mutations Cause a Treatable Malate-Aspartate Shuttle-Related Encephalopathy. Am J Hum Genet. Am J Hum Genet; 2019;105: 534–548. doi: 10.1016/j.ajhg.2019.07.015
- Bailis W, Shyer JA, Zhao J, Canaveras JCG, Al Khazal FJ, Qu R, et al.. Distinct modes of mitochondrial metabolism uncouple T cell differentiation and function. Nature. Nature; 2019;571: 403–407. doi: 10.1038/s41586-019-1311-3
- Chisolm DA, Savic D, Moore AJ, Ballesteros-Tato A, León B, Crossman DK, et al.. CCCTC-Binding Factor Translates Interleukin 2- and α-Ketoglutarate-Sensitive Metabolic Changes in T Cells into Context-Dependent Gene Programs. Immunity. NIH Public Access; 2017;47: 251–267.e7. doi: 10.1016/j.immuni.2017.07.015
- Hiemer S, Jatav S, Jussif J, Alley J, Lathwal S, Piotrowski M, et al.. Integrated Metabolomic and Transcriptomic Profiling Reveals Novel Activation-Induced Metabolic Networks in Human T Cells. SSRN Electron J. 2019; doi: 10.2139/ssrn.3473264
- Bettonville M, d’Aria S, Weatherly K, Porporato PE, Zhang J, Bousbata S, et al.. Long-term antigen exposure irreversibly modifies metabolic requirements for T cell function. Elife. 2018;7. doi: 10.7554/eLife.30938
- Ho M, Kim H. Glypican-3: a new target for cancer immunotherapy. Eur J Cancer. Eur J Cancer; 2011;47: 333–8. doi: 10.1016/j.ejca.2010.10.024
- Baumhoer D, Tornillo L, Stadlmann S, Roncalli M, Diamantis EK, Terracciano LM. Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples. Am J Clin Pathol. Am J Clin Pathol; 2008;129: 899–906. doi: 10.1309/HCQWPWD50XHD2DW6
- Ishiguro T, Sano Y, Komatsu SI, Kamata-Sakurai M, Kaneko A, Kinoshita Y, et al.. An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors. Sci Transl Med. Sci Transl Med; 2017;9. doi: 10.1126/scitranslmed.aal4291
- Moek KL, Fehrmann RSN, van der Vegt B, de Vries EGE, de Groot DJA. Glypican 3 Overexpression across a Broad Spectrum of Tumor Types Discovered with Functional Genomic mRNA Profiling of a Large Cancer Database. Am J Pathol. Am J Pathol; 2018;188: 1973–1981. doi: 10.1016/j.ajpath.2018.05.014
- Lu C, Rong D, Zhang B, Zheng W, Wang X, Chen Z, et al.. Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges and opportunities. Mol Cancer. BioMed Central; 2019;18: 130. doi: 10.1186/s12943-019-1047-6
- Wang X, He Q, Shen H, Xia A, Tian W, Yu W, et al.. TOX promotes the exhaustion of antitumor CD8+ T cells by preventing PD1 degradation in hepatocellular carcinoma. J Hepatol. J Hepatol; 2019;71: 731–741. doi: 10.1016/j.jhep.2019.05.015
- Engels B, Cam H, Schüler T, Indraccolo S, Gladow M, Baum C, et al.. Retroviral vectors for high-level transgene expression in T lymphocytes. Hum Gene Ther. Hum Gene Ther; 2003;14: 1155–68. doi: 10.1089/104303403322167993
- Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al.. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. Cancer Discov; 2012;2: 401–4. doi: 10.1158/-12-0095
- Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al.. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. Sci Signal; 2013;6: pl1. doi: 10.1126/scisignal.2004088
- Al-saraireh Y, Alrawashdeh F, Al-shuneigat J, Alsbou M, Alnawaiseh N, Al-shagahin H, et al.. Screening of Glypican- 3 Expression in Human Normal versus Benign and Malignant Tissues: A Comparative Study Glypican- 3 expression in cancers. Biosci Biotechnol Res Asia. 2016;13: 687–692. doi: 10.13005/bbra/2085
- Seo H, Chen J, González-Avalos E, Samaniego-Castruita D, Das A, Wang YH, et al.. TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+ T cell exhaustion. Proc Natl Acad Sci U S A. National Academy of Sciences; 2019;116: 12410–12415. doi: 10.1073/pnas.1905675116
- Khan O, Giles JR, McDonald S, Manne S, Ngiow SF, Patel KP, et al.. TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion. Nature. Nature Publishing Group; 2019;571: 211–218. doi: 10.1038/s41586-019-1325-x
- Gerlach C, Moseman EA, Loughhead SM, Garg R, De La Torre JC, Von UH, et al.. The Chemokine Receptor CX3CR1 Defines Three Antigen-Experienced CD8 T Cell Subsets with Distinct Roles in Immune Surveillance and Homeostasis Article The Chemokine Receptor CX3CR1 Defines Three Antigen-Experienced CD8 T Cell Subsets with Distinct Roles in Immune Surveillance and Homeostasis. Immunity. 2016;45: 1270–1284. doi: 10.1016/j.immuni.2016.10.018
- Majchrzak K, Nelson MH, Bailey SR, Bowers JS, Yu X-Z, Rubinstein MP, et al.. Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinic. Cancer Immunol Immunother. NIH Public Access; 2016;65: 247. doi: 10.1007/s00262-016-1797-6
- Araki K, Turner AP, Shaffer VO, Gangappa S, Keller SA, Bachmann MF, et al.. mTOR regulates memory CD8 T-cell differentiation. Nature. Nature; 2009;460: 108–12. doi: 10.1038/nature08155
- Alizadeh D, Wong RA, Yang X, Wang D, Pecoraro JR, Kuo C-F, et al.. IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype. Cancer Immunol Res. American Association for Cancer Research; 2019;7: 759–772. doi: 10.1158/2326-6066.CIR-18-0466
- Zhao Z, Condomines M, van der Stegen SJC, Perna F, Kloss CC, Gunset G, et al.. Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells. Cancer Cell. Cancer Cell; 2015;28: 415–428. doi: 10.1016/j.ccell.2015.09.004
- Scharping NE, Menk AV, Moreci RS, Whetstone RD, Dadey RE, Watkins SC, et al.. The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction. Immunity. Immunity; 2016;45: 374–88. doi: 10.1016/j.immuni.2016.07.009
- Patsoukis N, Bardhan K, Chatterjee P, Sari D, Liu B, Bell LN, et al.. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat Commun. Nat Commun; 2015;6: 6692. doi: 10.1038/ncomms7692
- Macintyre AN, Gerriets VA, Nichols AG, Michalek RD, Rudolph MC, Deoliveira D, et al.. The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function. Cell Metab. NIH Public Access; 2014;20: 61–72. doi: 10.1016/j.cmet.2014.05.004
- Ron-Harel N, Ghergurovich JM, Notarangelo G, LaFleur MW, Tsubosaka Y, Sharpe AH, et al.. T Cell Activation Depends on Extracellular Alanine. Cell Rep. Cell Rep; 2019;28: 3011–3021.e4. doi: 10.1016/j.celrep.2019.08.034
- Xu T, Stewart KM, Wang X, Liu K, Xie M, Ryu JK, et al.. Metabolic control of TH17 and induced Treg cell balance by an epigenetic mechanism. Nature. Nature; 2017;548: 228–233. doi: 10.1038/nature23475
Source: PubMed